home / stock / nvcr / nvcr quote
Last: | $12.32 |
---|---|
Change Percent: | -0.16% |
Open: | $12.36 |
Close: | $12.34 |
High: | $12.37 |
Low: | $11.88 |
Volume: | 716,400 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$12.32 | $12.36 | $12.34 | $12.37 | $11.88 | 716,400 | 04-25-2024 |
$12.34 | $12.09 | $12.34 | $12.39 | $12.02 | 1,076,800 | 04-24-2024 |
$12.055 | $11.7 | $12.055 | $12.46 | $11.7 | 747,026 | 04-23-2024 |
$11.83 | $12.19 | $11.83 | $12.19 | $11.7 | 809,482 | 04-22-2024 |
$12.09 | $11.89 | $12.09 | $12.32 | $11.89 | 850,446 | 04-19-2024 |
$12.05 | $12.05 | $12.05 | $12.445 | $11.89 | 1,392,284 | 04-18-2024 |
$12.05 | $12.4 | $12.05 | $12.45 | $12.04 | 1,361,232 | 04-17-2024 |
$12.46 | $12.56 | $12.46 | $12.71 | $12.2 | 923,876 | 04-16-2024 |
$12.72 | $13.6 | $12.72 | $13.72 | $12.63 | 1,168,309 | 04-15-2024 |
$13.57 | $14.01 | $13.57 | $14.12 | $13.4 | 901,798 | 04-12-2024 |
$14.12 | $14.9 | $14.12 | $15 | $14.025 | 831,697 | 04-11-2024 |
$14.62 | $14.48 | $14.62 | $14.74 | $14.1101 | 1,028,159 | 04-10-2024 |
$14.88 | $14.2 | $14.88 | $15.4622 | $14.18 | 969,689 | 04-09-2024 |
$14.18 | $13.8 | $14.18 | $14.21 | $13.62 | 1,130,832 | 04-08-2024 |
$13.74 | $14.06 | $13.74 | $14.24 | $13.62 | 1,389,954 | 04-05-2024 |
$14.29 | $14.6 | $14.29 | $14.785 | $14.22 | 1,173,634 | 04-04-2024 |
$14.42 | $14.08 | $14.42 | $14.79 | $14 | 1,365,359 | 04-03-2024 |
$14.39 | $15.12 | $14.39 | $15.15 | $14.07 | 1,388,858 | 04-02-2024 |
$15.49 | $15.63 | $15.49 | $15.63 | $14.98 | 1,673,857 | 04-01-2024 |
$15.63 | $14.55 | $15.63 | $16.05 | $14.38 | 2,811,987 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
NovoCure Limited Company Name:
NVCR Stock Symbol:
NASDAQ Market:
Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was...
Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, i...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three mo...